ABT vs LLY
ABT: A diversified global health care leader focused on diagnostic, medical device, nutritional, and pharmaceutical solutions. LLY: Eli Lilly is a global pharmaceutical innovator leading the market in metabolic health, including diabetes and obesity treatments, alongside a diverse portfolio of oncology and immunology therapies.
Side-by-side fundamentals
| Metric | ABT | LLY | Edge |
|---|---|---|---|
| Price as of 2026-08-24 close | $116.67 | $1,246.93 | |
| Market cap as of 2026-08-24 | $203.2B | $1.17T | |
| P/E as of 2026-08-24 | 37.55 | 41.85 | ABT lower |
| PEG as of 2026-08-24 | 3.63 | 1.48 | LLY lower |
| Net margin as of 2026-08-24 | +11.7% | +33.5% | LLY higher |
| Gross margin as of 2026-08-24 | +56.8% | +83.4% | LLY higher |
| Operating margin as of 2026-08-24 | +15.8% | +42.2% | LLY higher |
| ROE as of 2026-08-24 | +10.5% | +92.6% | LLY higher |
| ROA as of 2026-08-24 | +5.6% | +22.0% | LLY higher |
| Debt / equity as of 2026-08-24 | 0.64 | 1.62 | ABT lower |
| Revenue growth (YoY) as of 2026-08-24 | +8.1% | +49.6% | LLY higher |
| Revenue CAGR (3y) SEC XBRL | +0.5% | +31.7% | LLY higher |
| Dividend yield as of 2026-08-24 | +2.0% | +0.8% | ABT higher |
| Dividend streak (yrs) SEC XBRL | 4 | 5 | LLY higher |
| Beta as of 2026-08-24 | 0.18 | 0.55 | |
| 1-year return as of 2026-08-24 close | -12.0% | +75.2% | LLY higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.